Baseline Patient and Tumor Characteristics
Abbreviations: AI, aromatase inhibitor; EC-P, epirubicin and cyclophosphamide followed by paclitaxel; EP, epirubicin plus paclitaxel; OFS, ovarian function suppressor.Unless otherwise indicated, data are presented as No. (%) of patients. Percentages have been rounded and may not total 100.The regimens were changed during the endocrine therapy.